These results demonstrate that AAV843-mediated AGXT gene replacement is a safe and effective approach that achieves phenotypic correction in a murine model of PH1, warranting further evaluation in preclinical studies. This evidence concerns the gene AGXT and primary hyperoxaluria type 1.